Stellato, Daniel
Thabane, Marroon E.
Chandiwana, David
Park, Jinhee
Delea, Thomas E. http://orcid.org/0000-0001-5493-1925
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Accepted: 2 April 2021
First Online: 18 May 2021
Declarations
:
: Funding for this evaluation was provided by Novartis Pharmaceuticals Corp., East Hanover, NJ, USA.
: Thomas E. Delea is a partner at Policy Analysis Inc., a privately held, healthcare research consultancy that has received research funding and/or consulting fees from AbbVie, Alexion, Amgen, Bristol Myers Squibb, EMD Serono, GlaxoSmithKline, Jazz Pharmaceuticals, Lilly, Merck, Merck Group, Novartis, Pfizer, Sanofi, Seattle Genetics, and Takeda. Daniel Stellato is currently an employee of Policy Analysis Inc. David Chandiwana is an employee of Novartis and owns stock and/or stock options in Novartis. Marroon E. Thabane was an employee of Novartis at the time the study was conducted and owns stock and/or stock options in Novartis. Jinhee Park was an employee of Novartis at the time this evaluation was conducted and owns stock and/or options in Novartis.
: Not applicable.
: Not applicable.
: Not applicable.
: The information reported in this article and the supplementary material is sufficient to replicate the results of the study.
: The information reported in this article is sufficient to replicate the results of the study. The model used in the article includes a proprietary code and is not provided.
: All authors were involved with the conception and design of the evaluation, analysis and interpretation of the data, and drafting and critically revising the paper. All authors provided final approval and agreed to be accountable for the work reported herein.